Lampinen V, Gr xf6 hn S, Soppela S, Blazevic V, Hyt xf6 nen V, Hankaniemi M. SpyTag/SpyCatcher display of influenza M2e peptide on norovirus-like particle provides stronger immunization than direct genetic fusion. Front Cell Infect Microbiol. 2023;13:1216364 pubmed publisher

Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Flühler V, et al. Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine. Front Immunol. 2022;13:826164 pubmed publisher

Nemattalab M, Shenagari M, Taheri M, Mahjoob M, Nazari Chamaki F, Mojtahedi A, et al. Co-expression of Interleukin-17A molecular adjuvant and prophylactic Helicobacter pylori genetic vaccine could cause sterile immunity in Treg suppressed mice. Cytokine. 2020;126:154866 pubmed publisher

Magnusson S, Altenburg A, Bengtsson K, Bosman F, de Vries R, Rimmelzwaan G, et al. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66:224-233 pubmed publisher

Altenburg A, Magnusson S, Bosman F, Stertman L, de Vries R, Rimmelzwaan G. Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice. Clin Exp Immunol. 2017;190:19-28 pubmed publisher

Stavaru C, Onu A, Lupulescu E, Tucureanu C, Raşid O, Vlase E, et al. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant. Hum Vaccin Immunother. 2016;12:1009-26 pubmed publisher